Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. (Q39750666)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. |
scientific article |
Statements
Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease (English)
Adam Smith
Brian Giunta
Michael Fountain
Jun Tan
R Douglas Shytle
18 January 2010
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference